Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity

被引：2
作者：
von Itzstein, Mitchell S. [1 ,2 ]
Gerber, David E. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Hematol Oncol, Dallas, TX USA
[2] Univ Texas Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr, Peter ODonnell Jr Sch Publ Hlth, Dallas, TX USA
[4] Univ Texas Southwestern Med Ctr, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
CLINICAL CHEMISTRY | 2024年 / 70卷 / 04期
关键词：
D O I：
10.1093/clinchem/hvae021
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：571 / 573
页数：3
相关论文
共 50 条
[41]   Efficacy of Neoadjuvant Therapy for ROS1-Positive Locally-Advanced Lung Adenocarcinoma: A Case Report [J].
Chen, Rong ;
Wang, Guirong ;
Zhao, Jinlong ;
Liu, Yiqun .
AMERICAN JOURNAL OF CASE REPORTS, 2024, 25
[42]   TALETRECTINIB VS ENTRECTINIB IN ROS1-POSITIVE (ROS1+) NON-SMALL CELL LUNG CANCER (NSCLC): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) [J].
Nagasaka, Misako ;
Liu, Geoffrey ;
Pennell, Nathan A. ;
Perol, Maurice ;
Chen, Wenfeng ;
Bazhenova, Lyudmila ;
Zhou, Caicun .
VALUE IN HEALTH, 2025, 28 (06) :S51-S51
[43]   Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer [J].
Wu, Yi-Long ;
Yang, James Chih-Hsin ;
Kim, Dong-Wan ;
Lu, Shun ;
Zhou, Jianying ;
Seto, Takashi ;
Yang, Jin-Ji ;
Yamamoto, Noboru ;
Ahn, Myung-Ju ;
Takahashi, Toshiaki ;
Yamanaka, Takeharu ;
Kemner, Allison ;
Roychowdhury, Debasish ;
Paolini, Jolanda ;
Usari, Tiziana ;
Wilner, Keith D. ;
Goto, Koichi .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1405-+
[44]   Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan [J].
Nogami, Naoyuki ;
Nakamura, Atsushi ;
Shiraiwa, Naoko ;
Kikkawa, Hironori ;
Emir, Birol ;
Wiltshire, Robin ;
Morise, Masahiro .
FUTURE ONCOLOGY, 2023, 19 (37) :2453-2463
[45]   Real-World Outcomes Among Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [J].
Waterhouse, D. ;
Iadeluca, L. ;
Sura, S. ;
Zhou, J. ;
Wilner, K. ;
Emir, B. ;
Espirito, J. ;
Bartolome, L. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S317-S317
[46]   Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC) [J].
Nagasaka, M. ;
Liu, G. ;
Pennell, N. ;
Perol, M. ;
Chen, M. ;
Bazhenova, L. ;
Zhou, C. .
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03) :S1-S2
[47]   Phase II study of brigatinib in ROS1-positive non-small cell lung cancer patients previously treated with crizotinib [J].
Goto, Yasushi ;
Niho, Seiji ;
Daga, Haruko ;
Sakakibara-Konishi, Sakakibara-Konishi ;
Tanaka, Hiroshi ;
Ohashi, Kadoaki ;
Toyozawa, Ryo ;
Kotani, Masahiro ;
Takahashi, Toshiaki ;
Hattori, Yoshihiro ;
Morise, Masahiro ;
Ikeda, Takaya ;
Matsumoto, Shingo ;
Yoh, Kiyotaka ;
Nomura, Shogo ;
Goto, Koichi .
ANNALS OF ONCOLOGY, 2022, 33 :S475-S475
[48]   Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway [J].
Chen, Hui ;
Zhang, Qiang ;
Zhang, Yu ;
Jia, Bin ;
Zhang, Bin ;
Wang, Changli .
ONCOTARGETS AND THERAPY, 2018, 11 :8201-8209
[49]   Ceritinib in ROS1-positive non-small cell lung cancer patients: does clinical evidence carry clinical impact? [J].
Facchinetti, Francesco ;
Tiseo, Marcello .
TRANSLATIONAL CANCER RESEARCH, 2017, 6 :S1074-S1079
[50]   Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer [J].
Peters, Solange ;
Shaw, Alice T. ;
Besse, Benjamin ;
Felip, Enriqueta ;
Solomon, Benjamin J. ;
Soo, Ross A. ;
Bearz, Alessandra ;
Gadgeel, Shirish M. ;
Lin, Chia-Chi ;
Kao, Steven ;
Seto, Takashi ;
Masters, Elizabeth T. ;
Abbattista, Antonello ;
Clancy, Jill S. ;
Thurm, Holger ;
Reisman, Arlene ;
Peltz, Gerson ;
Camidge, D. Ross .
LUNG CANCER, 2020, 144 :10-19
12345